Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-gamma in Chronic Granulomatous Disease
NCT00001317Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 1992
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon gamma-1b in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Long-term side effects. Started May 1992; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT00001317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001317.